Impact of apheresis automation on procedure quality and predictability of CD34+ cell yield
- 23 March 2018
- journal article
- research article
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 33 (4) , 494-504
Abstract
Success of peripheral blood stem cell (PBSC) collections depends on patient biological parameters and stable apheresis device performance. We investigated product quality and factors influencing main apheresis procedure outcomes including CD34+ collection efficiency (CE), product volume or platelet CE. We also assessed different CD34+ cell yield prediction algorithms. Autologous PBSC collections by Spectra Optia from myeloma and lymphoma patients were analyzed. Complete blood count (CBC) from patient preprocedure and from collected products were assessed. (1) Product yield was calculated, (2) Product CBC was correlated with patient preprocedure variables, and (3) Predictions of CD34+ yields based on (a) product CD34+ cell concentration in samples after two or four chamber flushes or (b) traditional CE2 benchmark, were compared. 62 procedures in 41 patients were analyzed. 84% of all procedures were run without operator intervention. Median CD34+ CE2 was 56.9% (48.8%‐65.2%) and quite stable irrespective of patient conditions, with minor influence from patient white blood cell (WBC) precounts (rs = –.47; P < .001). Platelet loss correlated with WBC precount (rs = .46; P < .001), product volume (rs = .71; P < .0001) and number of chambers collected (rs = .72; P < .0001). CD34+ cell yield was better predicted based on (a) product CD34+ cell concentration from samples after 2 and 4 chamber flushes, respectively (rs = .969; P < .0001 and rs = .9648; P < .0001) than based on (b) CE2 formula (rs = .8262, P < .0001). Spectra Optia provides good quality PBSC products with stable and predictable yield regardless of starting conditions. CD34+ sampling of product after few chamber flushes could be used to predict CD34+ yield.Keywords
This publication has 20 references indexed in Scilit:
- Hematopoietic SCT in Europe: data and trends in 2011Bone Marrow Transplantation, 2013
- Allogeneic donor peripheral blood “stem cell” apheresis: prospective comparison of two apheresis systemsTransfusion, 2011
- Mobilized allogeneic peripheral stem/progenitor cell apheresis with Spectra Optia v.5·0, a novel, automatic interface‐controlled apheresis system: results from the first feasibility trialVox Sanguinis, 2011
- Automatic interface‐controlled apheresis collection of stem/progenitor cells: results from an autologous donor validation trial of a novel stem cell apheresis deviceTransfusion, 2010
- A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myelomaTransfusion, 2010
- Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous TransplantationTransplantation and Cellular Therapy, 2008
- Accurate prediction of autologous stem cell apheresis yields using a double variable‐dependent method assures systematic efficiency control of continuous flow collection proceduresVox Sanguinis, 2006
- Kinetic studies during peripheral blood stem cell collection show CD34+ cell recruitment intra‐apheresisJournal of Clinical Apheresis, 2001
- Monitoring of CD34+ cells during leukapheresis allows a single, successful collection of hemopoietic progenitors in patients with low numbers of circulating stem cellsBone Marrow Transplantation, 1999
- CD34 counts to predict the adequate collection of peripheral blood progenitor cellsBone Marrow Transplantation, 1997